A precise and non-toxic treatment that targets lung cancer cells at the nanoscale is able to effectively kill the cells even at a low dose.
Researchers from Washington State University and the Department of Energy’s Pacific Northwest National Laboratory (PNNL) used tiny tubes made from organic molecules called peptoids to deliver cancer-killing drugs in a targeted manner. The research, led by Yuehe Lin, professor in WSU’s School of Mechanical and Materials Engineering, and Chun-Long Chen, a senior research scientist at PNNL and a joint faculty fellow at the University of Washington, was published as the cover story in the prestigious journal Small.
The biologically-inspired nanotubes, which are about a hundred thousand times thinner than a human hair, were rolled up from membrane-like nanosheets. The drug molecules, fluorescent dyes and cancer-targeting molecules were precisely placed within the nanotubes, enabling them to track the efficiency of drug delivery into the cancer cells.
The new technology allows the two drugs – one for chemotherapy and the other for a less-invasive photodynamic therapy treatment – to be delivered directly to the cancer cells. Photodynamic therapy uses a chemical that, when exposed to light, releases reactive oxygen species (ROS) that kill cancer cells. The researchers’ dual-drug approach enabled the use of a lower dose of the cancer drugs than using a single drug, leading to effective killing of cancer cells with low toxicity.
“By precisely engineering these nanotubes with fluorescent dyes and cancer targeting molecules, scientists can clearly locate tumor cells and track how the drug regimen is performing,” said Lin. “We can also track how nanotubes enter and deliver the drugs inside the cancer cell.”
The team tested the nanotubes on lung cancer cells and found that they delivered the chemotherapy drug doxorubicin directly into the fast-dividing cancer cells, resulting in highly efficient cancer killing while using less chemotherapy drugs.
“This is a promising approach for precision targeting with little damage to healthy surrounding cells,” said Lin.
While other nanomaterials, such as carbon nanotubes, have been used to deliver and track cancer-killing drugs, researchers have found that they are toxic to the body. Furthermore, they didn’t do well at precisely recognizing molecules.
“By using these peptoids, we were able to develop highly programmable nanotubes and a biocompatible delivery mechanism,” said Chen. “We also harnessed the high stability of peptoid and its well-controlled packing to develop nanotubes that are highly stable.”
“Due to their unique structure, these nanotubes can be easily assembled for use in cancer therapy and stay in the body longer for treatment,” said Lin.
The team is now looking for collaboration and funding opportunities with pharmaceutical companies to extend the research into animal and clinical studies.
The Latest on: Lung cancer
via Google News
The Latest on: Lung cancer
- First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Studyon January 20, 2021 at 9:53 pm
Lung is being used for ctDNA testing and monitoring of patients treated with lorlatinib Study supported by a grant from Pfizer Inc. Research Triangle Park, NC, USA and Cambridge, UK, 20 January 2021 – ...
- Lung Cancer Screening Low-Dose CT Scan Provides Hope for a Cureon January 20, 2021 at 7:48 pm
Vic Thompson saw an advertisement for a lung cancer screening and decided to take action after 60 years of on-and-off smoking. After the lung cancer screening clinic determined that Vic was a ...
- Merck KGaA, GSK suffer lung cancer drug setbackon January 20, 2021 at 12:39 pm
Merck KGaA's drug development programme has suffered a setback with its most important experimental drug, cancer treatment bintrafusp alfa, failing early in its lead trial.
- Real-World Patients May Have More Side Effects to Immunotherapy for Lung Cancer Compared With Clinical Trial Dataon January 20, 2021 at 11:24 am
Findings from a study focused on patient-reported experiences, found that aching joints, aching muscles and fatigue were more common than initially found in clinical trials.
- Thinking about a lung cancer screening? This low-dose CT scan just might change everythingon January 20, 2021 at 11:02 am
When Vic Thompson saw an advertisement for a lung cancer screening, something prompted him, after about 60 years of on-and-off smoking, to look into it.
- Merck KGaA stops lung cancer trial testing drug hopeful bintrafusp alfaon January 20, 2021 at 10:06 am
Germany's Merck KGaA said the most important clinical trial testing its cancer drug hopeful bintrafusp alfa, which it is co-developing with GlaxoSmithKline, would be stopped because the treatment does ...
- GSK, German Merck's $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung canceron January 20, 2021 at 6:41 am
A drug that Pfizer passed over but saw a revitalized cancer R&D-focused GlaxoSmithKline jump on for $4.2 billion has come up as a dud in a key trial pitting it against U.S. Merck’s blockbuster ...
- Lung Cancer Diagnostics Market Trends, Analysis, Demand and Global Industry Research Report, Region, and Segment Forecasts, 2021-2027on January 20, 2021 at 3:46 am
The rising incidence of lung cancer is one of the significant factors influencing the growth of diagnostic procedures for the disease. Market Size – USD ...
- Lung cancer: Tripe palms are a warning sign of the deadly disease – what are they?on January 19, 2021 at 12:05 am
LUNG cancer is a serious disease with around 47,000 people being diagnosed with the condition every year in the UK. Tripe palms is a lesser-known warning sign.
- Study Finds No Association Between Autoimmune Disease and Lung Cancer Survivalon January 14, 2021 at 2:24 pm
Patients with both lung cancer and autoimmune disease have no significant difference in survival than patients with lung cancer alone, according to recent research from Northwestern University.
via Bing News